Study
Participants prescribed a gabapentinoid at baseline
Change in gabapentinoid use or prescribing
Number of participants who reported ADEs
Number of participants who reported SAEs
Pain and Quality of life outcomes
McDonald 2022
Intervention: 367 (16.3%) Control (usual care): 558 (20.9%) ­Gabapentinoid deprescribed (ceased)(by 3 business days) Intervention: 114 (35.3%) Control: 86 (21.2%)a
Not reportedb
Not reportedb
Not reportedc,d
Kasper 2014
Period 1 intervention: High dose pregabalin n = 206 Low dose pregabalin n = 206 Placebo groups n = N/A Period 2 intervention: High dose pregabalin n = 121 Low dose pregabalin n = 112 Placebo groups n = 77 ­Gabapentinoid use Intervention: 117/233 discontinued the pregabalin intervention (50.2%) Control: 51/77 completed the placebo intervention (66.2%) High dose n = 121 Low dose n = 121 Placebo n = NR High dose n = 27/154 Low dose n = 21 (plus one unrelated death)/154 Placebo n = NR Improved (HAM-A) High dose group: -18.7 (95%CI -20.0 to -17.3) Placebo high dose group: -17.5 (95%CI -19.8 to -15.2) Low dose group: -18.2 (95%CI -19.5 to -17.0) Placebo low dose group: -14.9 (95%CI -17.6 to -12.3)
Chazot 2021e
NR
Change in prescribing 12 months post intervention: Gabapentinoid from 12.9% (SD 3.46) to 2.54% (SD 2.9) (p = 0.032). Pregabalin from 3.24% (SD 1.89) to 15.0% (SD 2.28%) (p = 0.001)
NR
NR
NR
Collinson 2019e 144 Reduction in prescribing of 9.7% at 5 months NR NR NR